-
公开(公告)号:CA2917183C
公开(公告)日:2019-01-29
申请号:CA2917183
申请日:2014-07-22
Applicant: BASF SE
Inventor: HAFNER ANDREAS , BLATTER FRITZ , SZELAGIEWICZ MARTIN , SIEBENHAAR BERND , CHIODO TIZIANA , HINTERMANN TOBIAS , SALVADOR BEATE , VOSSEN MARCUS
IPC: C07D417/12 , A61K31/191 , A61K31/428 , A61K31/455 , A61K31/506 , C07C55/12 , C07D213/80 , C07D275/06
Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.
-
公开(公告)号:ES1221605U
公开(公告)日:2018-12-07
申请号:ES201890013
申请日:2017-11-02
Applicant: BASF SE , BASF CHINA CO LTD
Inventor: HINTERMANN TOBIAS , BUJARD PATRICE , KOSTRO ANDRE , VON MUEHLENEN ADRIAN , GARRIDO SEGURA CRISTOBAL
Abstract: 1. Sistema de iluminación de luz natural para la integración en un edificio o un vehículo, comprendiendo el sistema de iluminación de luz natural. Un elemento (800) de fachada translúcida o elemento de pared que contiene una lámina de vidrio y un elemento (302 o 708) de redirección de luz y un canal (801) de transporte de luz para guiar la luz aproximadamente horizontal hacia el interior del edificio o vehículo, el canal de transporte de luz que comprende una abertura conectada al lado interior de dicho elemento de fachada o elemento de pared y al menos una abertura hacia el interior del edificio o vehículo, caracterizado porque el elemento (302 o 708) de redirección de luz está formado como una película o lámina de polímero estructurada conectada a una lámina de vidrio del elemento (800) de fachada o elemento de pared y está configurado para cambiar la dirección de la luz incidente en el canal de transporte de luz aproximadamente.
-
公开(公告)号:AU2013333953B2
公开(公告)日:2017-08-31
申请号:AU2013333953
申请日:2013-10-16
Applicant: BASF SE
Inventor: CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SZELAGIEWICZ MARTIN , BLATTER FRITZ , RODEL EVA , VOSSEN MARCUS
IPC: C07D401/14 , A61K31/506 , A61P35/02
Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
-
公开(公告)号:AU2014295143A1
公开(公告)日:2016-02-11
申请号:AU2014295143
申请日:2014-07-22
Applicant: BASF SE
Inventor: HAFNER ANDREAS , BLATTER FRITZ , SZELAGIEWICZ MARTIN , SIEBENHAAR BERND , CHIODO TIZIANA , HINTERMANN TOBIAS , SALVADOR BEATE , VOSSEN MARCUS
IPC: C07D417/12
Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
-
公开(公告)号:AU2013276138A1
公开(公告)日:2015-01-22
申请号:AU2013276138
申请日:2013-06-13
Applicant: BASF SE
Inventor: CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SZELAGIEWICZ MARTIN , BLATTER FRITZ , SIEBENHAAR BERND , VOSSEN MARCUS
IPC: C07D417/12 , A61K31/506 , A61P35/00
Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 (INN: Dasatinib) and a second compound selected from methyl-4-hydroxybenzoate, or nicotinamide, or ethyl gallate, or methyl gallate, or propyl gallate, or ethyl maltol or vanillin, or men- thol, or (1R,2S,5R)-(-)-menthol,as well as to a process for obtaining the same.
-
公开(公告)号:AT445672T
公开(公告)日:2009-10-15
申请号:AT06708681
申请日:2006-03-08
Applicant: BASF SE
Inventor: SCHAEFER THOMAS , HINTERMANN TOBIAS , SCHMIDHALTER BEAT , BARDON KRISTINA , MURER PETER
IPC: C08L65/00 , C07C211/00
Abstract: The present invention relates to polymers comprising a repeating unit of the formula (I), and their use in electronic devices. The polymers according to the invention have excellent 5 solubility in organic solvents and excellent film-forming properties. In addition, high charge carrier mobilities and high temperature stability of the emission color are observed, if the polymers according to the invention are used in polymer light emitting diodes (PLEDs).
-
公开(公告)号:ES2720595T3
公开(公告)日:2019-07-23
申请号:ES10747638
申请日:2010-09-01
Applicant: BASF SE
Inventor: HINTERMANN TOBIAS , BAUER DIDIER , CARROY ANTOINE , LORDELOT CAROLINE , KOHLI STECK RACHEL
Abstract: Compuestos catalíticos de quelato de Ti de fórmula I**Fórmula** en la que R1 denota fenilo, ambos de los cuales están sustituidos con uno o más R'2, R'3 o R'4; o los dos R1 juntos son alquileno C1-C8 lineal o ramificado no sustituido, alquileno C1-Ca lineal o ramificado que está sustituido con uno o más fenilo o benzoilo, o los dos R1 juntos son fenileno o bifenileno, en donde dicho fenileno o bifenileno no están sustituidos o están sustituidos por uno o más R'2, R'3 o R'4; R2, R3 y R4, independientemente entre sí, son hidrógeno, alquilo C1-C12 o alcoxi C1-C12 lineal o ramificado; R'2, R'3 y R'4, independientemente entre sí, son hidrógeno o alquilo C1-C4 lineal o ramificado; R5, R6 y R7, independientemente entre sí, son hidrógeno o alquilo C1-C4 lineal o ramificado, siempre que no más de uno de R5, R6 y R7 sea hidrógeno.
-
公开(公告)号:BR112012005902A2
公开(公告)日:2016-03-15
申请号:BR112012005902
申请日:2010-09-09
Applicant: BASF SE
Inventor: CARROY ANTOINE , LORDELOT CAROLINE , BAUER DIDIER , STECK RACHEL KOHLI , HINTERMANN TOBIAS
Abstract: formulação de catalisador de quelato de ti, uso da formulação de catalisador de quelato de ti ou de um composto, composição processo para a polimerização de compostos, catalisador de quelato de ti, uso da composição polimerizável, e, substrato revestido. apresente invenção provê uma formulação de catalisador de quelato de titânio fotolatente, que compreende (i) pelo menos um composto da fórmula i (i), em que r~1~ é alquila c~1~-c~20~ou alquila c~2~-c~20~,=, que é interrompido por um ou mais átomos de o não- consecutivos; y é ou fenila opcionalmente substituído; y~1~ é ou fenila opcionalmente substituído; y~2~ é ou fenila opcionalmente substituído; y~3~ ou fenila opcionalmente substituído; r~2~, r~3~, r~4~, r~5~, r~6~, r~7~, r~8~, r~9~, r~10~, r~11~, r~12~ e r~13~, independentemente um do outro , são cada qual hidrogênio, halogênio, alquila c~1~-c~20~ opcionalmente substituído, ou r~2~, r~3~, r~4~, r~5~, r~6~, r~7~, r~8~, r~9~, r~10~, r~11~, r~12~ e r~13~ independentemente um do outro, são cada qual arila c~6~ -c~14~ opcionalmente substituído, contanto que apenas um de r ~2~, r~3~, r~4~ seja hidrogênio e apenas um de r~5~, r~6~, r~7~ seja hidrogênio e apenas um de r~8~, r~9~, r~10~ seja hidrogênio, e apenas um de r~11~, r~12~,r~13~ seja hidrogênio; e (ii) pelo menos um composto ligante de quelato da fórmula iia, iib ou iic em que, y é r ~2~, r ~3~, r ~4~, r ~5~, r ~6~ e r ~7~ independentemente um do outro, possuem os significados, tais que dadaos para r~2~, r~3~, r~4~, r~5~, r~6~, r~7~, r~8~, r~9~, r~10~, r~11~, r~12~ e r~13~; e r ~14~, r~15~ e r~16~ independentemente um do outros, possuem os significados como fornecidos para r~14~, r~15~ e r~16~.
-
公开(公告)号:AU2013333953A1
公开(公告)日:2015-04-30
申请号:AU2013333953
申请日:2013-10-16
Applicant: BASF SE
Inventor: CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SZELAGIEWICZ MARTIN , BLATTER FRITZ , RODEL EVA , VOSSEN MARCUS
IPC: C07D401/14 , A61K31/506 , A61P35/02
Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
-
公开(公告)号:CA2887540A1
公开(公告)日:2014-04-24
申请号:CA2887540
申请日:2013-10-16
Applicant: BASF SE
Inventor: CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SZELAGIEWICZ MARTIN , BLATTER FRITZ , RODEL EVA , VOSSEN MARCUS
IPC: C07D401/14 , A61K31/506 , A61P35/02
Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
-
-
-
-
-
-
-
-
-